Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 29 May 2020, 14:54 HKT/SGT
Share:
    

Source: Eisai
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
Concerning the Dosage and Administration Related to the Indication of Hidradenitis Suppurativa

TOKYO, May 29, 2020 - (JCN Newswire) - AbbVie GK and Eisai Co., Ltd. today announced an approval of partial changes in the marketing approval of HUMIRA (generic name: adalimumab [recombinant], hereafter "HUMIRA"), a fully human anti-TNFalpha monoclonal antibody, for additional dosage and administration, specifically, to add an 80mg every-other-week (Q2W) regimen as a treatment option for patients with hidradenitis suppurativa (HS) after the first 4 weeks of treatment.

Previously, the recommended dose of HUMIRA for HS patients was 160 mg in week 0, followed by 80 mg two weeks later, administered by subcutaneous injection. Starting at week 4, HUMIRA should be administered at a dose of 40mg once weekly (QW). Today, an 80mg Q2W regimen has been newly added as a treatment option with efficacy and safety equivalence to those of the 40mg QW regimen. 80mg Q2W is expected to contribute to reducing patients' burden of injection by reducing the number of administrations by half* and extend the administration interval in comparison to 40mg QW.

*When HUMIRA Subcutaneous Injection 80 mg Syringe 0.8 mL or HUMIRA Subcutaneous Injection 80 mg Pen 0.8 mL is used.

This approval was supported by the results of efficacy and safety evaluations at 80mg Q2W for HUMIRA in a Japanese phase III study (Study M15-573) and the results obtained by simulation with data in clinical pharmacokinetic studies. The Japanese phase III study was a multi-center, open-label, single-arm study to evaluate the efficacy and safety of HUMIRA in Japanese patients with moderate to severe HS.

HUMIRA was designated as an orphan drug for the indication of HS in 2017 and was approved for the first time in Japan for the indication of HS on February 21, 2019. Currently, HUMIRA is the only drug that has an indication for HS in Japan.

HS is a painful, inflammatory skin disease with a chronic course which typically presents after puberty. Inflammatory symptoms are frequently observed in the axillary, inguinal, breast-fold, and gluteal regions. The main symptom is red, swollen boil-like lumps, and the progression of symptoms leads to formation of nodules, abscesses, and even fistulas. Repeated recurrence causes thickening of the affected areas, resulting in scarring.(1) Severe symptoms may limit the patients' daily activities and sometimes force them to stop working.(2) The epidemiology data in Japan is unknown,(3) and the prevalence outside Japan is reported to be 1%.(4) Since the disease is poorly recognized and difficult to diagnose, overseas reports indicate that the average time to definitive diagnosis is seven years, which is longer than that of psoriasis and other inflammatory skin diseases, and patients with HS visit hospitals more often.

AbbVie and Eisai are committed to further contribute to the improvement of QOL of many more patients by making efforts to promote the appropriate use of HUMIRA, including its use for this indication, and to provide information on HUMIRA.

About HUMIRA

HUMIRA is a fully human anti-TNFα monoclonal antibody. In Japan, it is approved for "the treatment of rheumatoid arthritis (including inhibition of the progression of structural damage); hidradenitis suppurativa; plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis*, intestinal Behcet's disease, and non-infectious intermediate, posterior or panuveitis that are refractory to the conventional therapies; induction and maintenance therapy for moderate to severely active Crohn's disease (limited to cases of inadequate response to conventional therapy); and treatment of moderate to severe ulcerative colitis (limited to cases of inadequate response to conventional therapy)."

*HUMIRA for Subcutaneous Injection 20mg Syringe 0.2mL is approved. HUMIRA for Subcutaneous Injection 80mg Syringe 0.8 mL and HUMIRA for Subcutaneous Injection 80mg Pen 0.8 mL are yet to be approved for this indication.

Nonproprietary name: Adalimumab (Genetical Recombination)
Brand name: HUMIRA, a fully human anti-TNFalpha monoclonal antibody, "Subcutaneous
Injection 20mg Syringe 0.2 mL, 40mg Syringe 0.4 mL, 80mg Syringe 0.8 mL, 40mg Pen 0.4 mL, 80mg Pen 0.8 mL"

(1) Hunger RE, et al. Dermatology. 2017 Jul 7. doi: 10.1159/000477459.
(2) Jemec G. Clinical and experimental dermatology., 1996, Vol.21(6), p.419-423
(3) Nobukazu Hayashi et.al., Journal of the Japan Organization of Clinical Dermatologists, 35(4);601-609, 2018
(4) Revuz J., J Eur Acad Dermatol Venereol. 2009 Sep;23(9):985-98.

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com.


About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:
AbbVie Inc.
1 North Waukegan Road North Chicago, IL 60064
+1 (847) 938-9190
abbvie.com 
35V-1940051

Eisai Co., Ltd.
Public Relations Department
+81(0)3-3817-5120


May 29, 2020 14:54 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 6, 2020 08:33 HKT/SGT
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
July 6, 2020 08:05 HKT/SGT
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan
July 1, 2020 13:02 HKT/SGT
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID
June 25, 2020 10:47 HKT/SGT
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea
June 10, 2020 12:49 HKT/SGT
Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa
June 4, 2020 10:43 HKT/SGT
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
June 2, 2020 10:05 HKT/SGT
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
May 29, 2020 10:31 HKT/SGT
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 18, 2020 12:33 HKT/SGT
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 14, 2020 08:22 HKT/SGT
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: